Johnson & Johnson Debt to Equity Ratio 2010-2024 | JNJ
Current and historical debt to equity ratio values for Johnson & Johnson (JNJ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Johnson & Johnson debt/equity for the three months ending March 31, 2024 was 0.38.
| Johnson & Johnson Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-03-31 |
$0.00B |
|
0.00 |
| 2023-12-31 |
$98.78B |
$68.77B |
1.44 |
| 2023-09-30 |
$94.83B |
$71.23B |
1.33 |
| 2023-06-30 |
$115.28B |
$76.41B |
1.51 |
| 2023-03-31 |
$125.10B |
$70.87B |
1.77 |
| 2022-12-31 |
$110.57B |
$76.80B |
1.44 |
| 2022-09-30 |
$100.53B |
$74.60B |
1.35 |
| 2022-06-30 |
$101.37B |
$76.36B |
1.33 |
| 2022-03-31 |
$103.65B |
$74.71B |
1.39 |
| 2021-12-31 |
$108.00B |
$74.02B |
1.46 |
| 2021-09-30 |
$108.96B |
$70.27B |
1.55 |
| 2021-06-30 |
$106.86B |
$69.58B |
1.54 |
| 2021-03-31 |
$106.72B |
$65.83B |
1.62 |
| 2020-12-31 |
$111.62B |
$63.28B |
1.76 |
| 2020-09-30 |
$106.22B |
$64.47B |
1.65 |
| 2020-06-30 |
$95.40B |
$62.98B |
1.52 |
| 2020-03-31 |
$93.72B |
$61.29B |
1.53 |
| 2019-12-31 |
$98.26B |
$59.47B |
1.65 |
| 2019-09-30 |
$97.31B |
$58.21B |
1.67 |
| 2019-06-30 |
$94.33B |
$60.79B |
1.55 |
| 2019-03-31 |
$91.07B |
$58.96B |
1.55 |
| 2018-12-31 |
$93.20B |
$59.75B |
1.56 |
| 2018-09-30 |
$91.08B |
$64.63B |
1.41 |
| 2018-06-30 |
$92.48B |
$62.89B |
1.47 |
| 2018-03-31 |
$93.37B |
$63.26B |
1.48 |
| 2017-12-31 |
$97.14B |
$60.16B |
1.62 |
| 2017-09-30 |
$81.68B |
$73.98B |
1.10 |
| 2017-06-30 |
$80.89B |
$71.92B |
1.13 |
| 2017-03-31 |
$74.58B |
$70.34B |
1.06 |
| 2016-12-31 |
$70.79B |
$70.42B |
1.01 |
| 2016-09-30 |
$67.60B |
$72.77B |
0.93 |
| 2016-06-30 |
$67.34B |
$72.47B |
0.93 |
| 2016-03-31 |
$63.58B |
$72.65B |
0.88 |
| 2015-12-31 |
$62.26B |
$71.15B |
0.88 |
| 2015-09-30 |
$61.71B |
$71.55B |
0.86 |
| 2015-06-30 |
$60.91B |
$71.13B |
0.86 |
| 2015-03-31 |
$60.71B |
$67.88B |
0.89 |
| 2014-12-31 |
$60.61B |
$69.75B |
0.87 |
| 2014-09-30 |
$55.51B |
$76.59B |
0.73 |
| 2014-06-30 |
$57.15B |
$78.05B |
0.73 |
| 2014-03-31 |
$56.75B |
$76.58B |
0.74 |
| 2013-12-31 |
$58.63B |
$74.05B |
0.79 |
| 2013-09-30 |
$57.13B |
$69.80B |
0.82 |
| 2013-06-30 |
$54.66B |
$69.67B |
0.79 |
| 2013-03-31 |
$54.68B |
$66.86B |
0.82 |
| 2012-12-31 |
$56.52B |
$64.83B |
0.87 |
| 2012-09-30 |
$55.19B |
$63.76B |
0.87 |
| 2012-06-30 |
$55.32B |
$60.43B |
0.92 |
| 2012-03-31 |
$54.83B |
$61.37B |
0.89 |
| 2011-12-31 |
$56.56B |
$57.08B |
0.99 |
| 2011-09-30 |
$50.29B |
$61.53B |
0.82 |
| 2011-06-30 |
$49.98B |
$62.13B |
0.80 |
| 2011-03-31 |
$48.29B |
$59.86B |
0.81 |
| 2010-12-31 |
$46.33B |
$56.58B |
0.82 |
| 2010-09-30 |
$40.96B |
$57.29B |
0.72 |
| 2010-06-30 |
$39.45B |
$52.85B |
0.75 |
| 2010-03-31 |
$40.53B |
$52.91B |
0.77 |
| 2009-12-31 |
$44.09B |
$50.59B |
0.87 |
| 2009-09-30 |
$41.17B |
$50.38B |
0.82 |
| 2009-06-30 |
$41.19B |
$46.25B |
0.89 |
| 2009-03-31 |
$42.31B |
$43.79B |
0.97 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$348.864B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
